Not Signed In - Manhattan Pharmaceuticals Expands Phase 2a Obesity Clinical Trial Sites To US
Thu, 09 Nov 2006 08:00 AM EST
... Manhattan Pharmaceuticals, Inc. (Amex: MHA) today announced that it has expanded the clinical trial sites for its ongoing Phase 2a study of oral Oleoyl-estrone (OE) in obese adult subjects to the United States. OE is the Company's orally administered product candidate in development for the treatment of obesity. [click link for full article] ...
Related Topics
- Clinical Trials
- Obesity
- Overweight and Obesity
- Obesity and Overweight
- Interferon Alfa-2a
- Pharmacology
- Trastuzumab
- Psychopharmacology
- Peginterferon alfa-2a
- Tarceva
- Dilation And Curettage
- Infection at other sites
- Food Recommendations: South Beach Diet - Phase 1
- Food Recommendations: South Beach Diet - Phase 2
- Spread of Candida to other sites
- Clinical Growth Charts
- Bevacizumab Injection
- Crohn's Disease
- Pancreatic Cancer
- Patient Issues
email this page
print this page
bookmark this page
feedback on this page
